Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines

The new vaccines for coronavirus disease 2019 (COVID-19) are highly effective, but controversy exists about whether a second dose should be delayed in order to immunize more people. The second dose is necessary and should be given.

Messenger RNA (mRNA) is a highly unstable molecule that is used to create proteins in cells. mRNA can be synthesized in a laboratory and, when injected into cells, can cause pieces of proteins to be made. When these small pieces of protein (peptides) leave the cell, the body can develop an immune reaction to them. The 2 main vaccines in the US from Pfizer and Moderna use this approach to vaccinate people against COVID-19 infection.

5 Comments for this article

EXPAND ALL

February 3, 2021

mRNA Vaccine Endpoints: Disease vs Infection

David Dassey, MD, MPH | Retired medical epidemiologist

This guidance states that the purpose of mRNA vaccines is to induce immunity to COVID-19 infection. Actually, the primary end point in both vaccine studies was to reduce clinical disease, not to prevent SARS-CoV-2 infection. Furthermore use of the phrase "COVID-19 infection," while commonly used by the media, is inaccurate since COVID-19 is a disease caused by infection with the novel virus SARS-CoV-2. As stated in the cited CDC reference: "The Advisory Committee on Immunization Practices (ACIP) has issued interim recommendations for the use of Pfizer-BioNTech and Moderna COVID-19 vaccines for the prevention of coronavirus disease 2019 (COVID-19) in the United States."

Both Pfizer/BNT and Moderna are continuing their research to determine if indeed these vaccines actually do prevent viral infection. If this is confirmed, there will be a much greater chance of rapidly reducing ongoing transmission by herd immunity and allowing relaxation of nonpharmaceutical prevention strategies. Until such time, all we can claim about these vaccines is that they both greatly reduce the incidence of serious and fatal infections, but not that they reduce infections per se.

CONFLICT OF INTEREST: None Reported

February 4, 2021

Two vs Single Doses

Rashmi Patel, MD PhD | King's College London

While immunologically naive individuals will likely require two doses to stimulate longer-lasting immunological memory to SARS-CoV-2 following COVID-19 illness, this may not necessarily be the case for people who have already developed an antibody response to natural infection. A recent preprint suggested substantial and rapidly rising antibody titres following a single dose of a COVID-19 mRNA vaccine in people who were seropositive prior to vaccination, possibly due to an anamnestic response to already-established immunological memory [1]. It is worth considering this point in light of limited vaccine supplies.

1. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. Florian Krammer, Komal Srivastava, the PARIS team, Viviana Simon. medRxiv 2021.01.29.21250653; doi: https://doi.org/10.1101/2021.01.29.21250653

CONFLICT OF INTEREST: None Reported

February 7, 2021

Where Are Data on Secretory IgA?

Vin LoPresti, PhD Cell Biology | Retired Professor of BioScience, Former Senior Science Writer, Los Alamos National Lab

As some writers have noted, the lack of full transparency by Pfizer & Moderna means we are really discussing this topic only in the most general terms. More important is the question of what specific aspects of immunity are elicited by one-shot or two-shot mRNA vaccines. For example, do we see respectable IgG and IgA titers? With a vigorous secretory IgA (sIgA) response at mucosal surfaces, we might be feeling better about an individual's post-vaccination status because sIgA at those surfaces could diminish viral shedding, thereby reducing transmission to the remaining unvaccinated population. This could make that twice-vaccinated individual much less likely to shed residual virus afterward. This is an unresolved question, and pertinent data from the vaccine manufacturers should be demanded by government agencies.

Sure, memory immune responses most often do generate specific antibodies across the classes. And while it appears that both IgG and sIgA are present in individuals recovered from COVID, we can't simply assume that status for a novel method of injectable vaccine delivery (as we might for an oral or nasal vaccine as second-dose). With the slow pace of distribution at only around 10% vaccinated, this is quite relevant to that 90-10 situation, and might not matter as much if we were up at 70–80% vaccinated. (There is, in fact, at least one developed oral vaccine, purportedly in Phase 1 trials.)

It's truly painful to watch this unfold as healthcare and government agencies simply accept the data crumbs that the manufacturers are willing to throw us rather than demanding complete Phase 3 trial data.

CONFLICT OF INTEREST: None Reported

March 29, 2021

Efficacy of First Dose

Judy Mourant, PhD |

Table 15 of Moderna's briefing document says that 14 days after the first dose, vaccine efficacy is 92% (CI: 69% - 99%) (1).

What is the reference for the statement "a relatively weak immune reaction was found within a few weeks after people received the first dose of vaccine?"

Reference

1. https://www.fda.gov/media/144434/download

CONFLICT OF INTEREST: None Reported

March 31, 2021

Confounding two issues?

Gerald Silverberg, BA | UNU-MERIT and IIASA

This article seems to confound two unrelated issues: whether it is necessary to get a second dose of the Moderna and BioNTech/Pfizer vaccines, and whether extending the interval between doses is advisable now in order to inoculate more people in an emergency situation.

No one disputes that the former is true, but this says nothing about the latter issue. The present approved intervals, 3 weeks for bioNTech/Pfizer and 4 for Moderna, are what was used for the clinical trials but have never been shown to be optimal. The number of clinical trials to establish optimality would obviously be prohibitive. For the AstraZeneca vaccine, extending to 12 weeks actually seems more efficacious.

The upside to extending the interval is obvious: appreciably more people can get at least a first dose. And first doses of the mRNA vaccines have been shown to provide >90% protection against disease and >80% against infection, and last for at least several weeks if not months. In the race against new variants of concern, this could be decisive.

What are the downsides of extending the interval? Marginally lower protection for the period of one dose. The possibility of promoting the emergence of new variants during the interval of partial protection. But completely unvaccinated individuals can also breed new variants, and in fact that's how the current generation of new variants emerged. So on balance this is an upside, not a downside.

In any event the two issues should not be confused.

CONFLICT OF INTEREST: None Reported

Trending

Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines

Others Also Liked

Special Communications

Blogs

Trending

Select Your Interests

Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines

Thank You.

See More About

Citation

Download citation file:

Others Also Liked

Sign in to access your subscriptions

Purchase access

Sign in to download free article PDFs

Sign in to access your subscriptions

Get free access to newly published articles

Sign in to access your subscriptions

Purchase access

Sign in to save your search

Purchase access

Sign in to save your search

Purchase access

Sign in to customize your interests

Get free access to newly published articles

Sign in to make a comment

Get free access to newly published articles